Resolutions of the Annual General Meeting of Evotec AG

Resolutions of the Annual General Meeting of Evotec AG

  *Actions of Management Board and Supervisory Board approved
  *Dr Walter Wenninger becomes new Chairman of the Supervisory Board
  *Dr Claus Braestrup elected as new member of the Supervisory Board
  *Fixed remuneration for the Supervisory Board concluded

HAMBURG, Germany, June 12, 2013 (GLOBE NEWSWIRE) -- Shareholders of Evotec AG
(Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) today approved the actions of the
members of the Management Board and the Supervisory Board for the fiscal year
2012 at the Annual General Meeting.

The Chief Executive Officer of Evotec AG, Dr Werner Lanthaler, presented the
Company's performance for the year 2012 and provided the shareholders with an
update on the topic innovation efficiency within Action Plan 2016.

Furthermore, the Annual General Meeting elected Dr Claus Braestrup as new
member of the Supervisory Board. Dr Braestrup has extensive experience in
executive-level functions at international pharmaceutical companies – among
others as former President and CEO and Head of Research and Development of
Lundbeck A/S and as Vice President for pharmaceutical research at Novo Nordisk
A/S. His special skills in the area of drug research are of great value for
his task within the Supervisory Board.

Dr Braestrup succeeds Dr Flemming Ørnskov until the completion of the Annual
General Meeting 2014. Dr Ørnskov resigned as member and Chairman of the
Supervisory Board upon conclusion of the Annual General Meeting 2013. In a
subsequent meeting of the Supervisory Board, Dr Walter Wenninger, former
Deputy Chairman of the Supervisory Board, was elected as Chairman of the
Supervisory Board and Mr Roland Oetker was elected as his Deputy Chairman.

"I'd like to express my sincere gratitude to Dr Ørnskov, also on behalf of my
colleagues in the Management Board, for his constructive and successful
collaboration over the last years. We wish him all the best for realising his
professional and personal objectives", said Dr Werner Lanthaler, Chief
Executive Officer of Evotec. "At the same time, I'd like to warmly welcome Dr
Claus Braestrup to the Evotec Supervisory Board."

The Annual General Meeting also approved the proposal of the Management Board
and the Supervisory Board to change the remuneration of the Supervisory Board
to a fixed remuneration in form of cash compensation from fiscal year 2013
onwards. Moreover, the Annual General Meeting passed all of the other agenda
items requiring shareholders' approval, thereunder the resolution on single
amendments of the articles of association and the appointment of KPMG as the
auditor for fiscal year 2013.

At the ordinary Annual General Meeting 2013 of Evotec AG, 40.5% of the voting
capital was present.

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing the
highest quality stand-alone and integrated drug discovery solutions, covering
all activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and expertise
in key therapeutic areas including neuroscience, pain, metabolic diseases as
well as oncology and inflammation. Evotec has long-term discovery alliances
with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen
Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition,
the Company has existing development partnerships and product candidates both
in clinical and pre-clinical development. These include partnerships with
Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes,
with Janssen Pharmaceuticals in the field of depression and with Roche in the
field of Alzheimer's disease. For additional information please go to
www.evotec.com.

FORWARD LOOKING STATEMENTS — Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT: Gabriele Hansen
         Head of Corporate Communications
         +49.(0)40.560 81-255
         +49.(0)40.560 81-222 Fax
         gabriele.hansen@evotec.com
        
         Evotec AG
         Manfred Eigen Campus
         Essener Bogen 7
         22419 Hamburg (Germany)